Sequent Scientific Financial Statements

Sequent Scientific (SEQUENT) reported revenue of ₹15.51B in FY2025 with net income of ₹322.59M. Total assets stood at ₹16.02B and free cash flow was ₹442.75M.

Sequent Scientific Income Statement

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Revenue		13.62B	14.24B	14.27B	13.81B	15.51B
Cost of Rev. Cost of Revenue		-6.95B	-7.93B	-8.34B	-7.60B	-8.12B
Gross Profit		6.67B	6.31B	5.94B	6.21B	7.40B
SGA Sales, General & Admin		-4.55B	-5.10B	-5.75B	-5.49B	-5.81B
Op. Income Operating Income		1.61B	691.60M	-373.48M	108.31M	924.15M
PBT Profit Before Tax		1.37B	533.86M	-1.38B	-546.46M	443.06M
Net Income		954.42M	450.60M	-1.22B	-296.13M	322.59M
Dil. Shares Diluted Shares		245.31M	250.73M	250.11M	249.88M	256.27M
Diluted EPS		3.89	1.65	-4.88	-1.44	0.85

Figures in ₹ — millions (M), billions (B), trillions (T). EPS is earnings per share.

Understanding the Income Statement

The income statement shows Sequent Scientific's revenue and expenses over a period. Revenue minus costs gives gross profit; after operating expenses, interest, and taxes, the remainder is net income. Diluted EPS divides net income by all shares that could exist if options and convertibles were exercised.

Sequent Scientific Balance Sheet

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Curr. assets Total current assets		7.14B	7.83B	7.80B	8.11B	8.73B
Non-curr. assets Total non-current assets		6.79B	6.68B	7.49B	7.29B	7.29B
Total assets		13.93B	14.51B	15.29B	15.40B	16.02B
Curr. liabilities Total current liabilities		4.61B	5.12B	5.59B	6.27B	5.05B
Non-curr. liab. Total non-current liabilities		1.55B	1.99B	2.21B	2.00B	3.27B
Total liabilities		6.16B	7.11B	7.80B	8.27B	8.32B
Total equity		7.76B	7.40B	7.49B	7.13B	7.70B
Total liab. & eq. Total liabilities & equity		13.93B	14.51B	15.29B	15.40B	16.02B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding the Balance Sheet

The balance sheet captures Sequent Scientific's financial position at a point in time — what it owns (assets), what it owes (liabilities), and the residual value to shareholders (equity). Total assets always equals total liabilities plus equity.

Sequent Scientific Cash Flow Statement

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Net Income		1.45B	529.30M	-1.38B	-546.46M	443.06M
Operating CF Cash flow Operating Activities		1.15B	305.95M	168.08M	305.95M	833.62M
Capex Investments in PPE		-528.30M	-324.64M	-861.79M	-308.07M	-390.87M
Investing CF Cash flow Investing Activities		96.48M	-955.66M	-649.58M	-59.20M	-247.78M
Dividend Paid		-14.25M	-123.44M	0	0	0
Financing CF Cash flow Financing Activities		-1.39B	672.57M	322.28M	-14.39M	-607.34M
Cash (start) Cash at beginning of period		68.10B	537.44M	574.96M	415.74M	648.10M
Cash (end) Cash at end of period		537.44M	574.96M	415.74M	648.10M	626.60M
FCF Free Cash Flow		619.24M	-18.69M	-693.71M	-2.12M	442.75M

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding Cash Flow

The cash flow statement tracks how Sequent Scientific's cash moves through operations, investing, and financing activities. Free cash flow — operating cash minus capital expenditure — shows what is available to return to shareholders.

Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025